Orchard Therapeutics Announces Reimbursement Agreement for Libmeldy

News
Article

Orchard Therapeutics announces reimbursement agreement, which will make Libmeldy available for all eligible MLD patients in Italy.

Orchard Therapeutics, a global gene therapy company, announced on April 11, 2022 that it has reached a reimbursement agreement with the Italian Medicines Agency to enable access to Libmeldy (atidarsagene autotemcel) for all children with metachromatic leukodystrophy (MLD) who fall within the scope of the European marketing authorization.

MLD is a rare and life-threatening inherited disease of the body’s metabolic system that occurs in approximately one in every 100,000 live births. It is caused by a mutation in the arylsulfatase-A (ARSA) gene that results in the accumulation of sulfatides in the brain, liver, gallbladder, kidneys, and/or spleen. Patients with MLD gradually lose the ability to move, talk, swallow, ear, and see.

“Following the February announcement of our landmark reimbursement agreement with NHS England, we are pleased that the Italian Medicines Agency has recognized the significant potential clinical benefit Libmeldy offers, granting it innovative status and agreeing to reimburse the therapy for all eligible MLD patients in the country,” said Braden Parker, chief commercial officer of Orchard Therapeutics, in a press release. “The momentum on our reimbursement negotiations is encouraging, as is our early progress in identifying patients in both Europe and the Middle East who may benefit from this therapy.”

Source: Orchard Therapeutics

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes